Desitin Arzneimittel Gmbh

Apnimed's Sulthiame Shows Promise in Phase 2 Trial for Obstructive Sleep Apnea, Results Published in The Lancet

- Apnimed's Phase 2 FLOW study of sulthiame, an oral carbonic anhydrase inhibitor, met its primary endpoint across all doses in treating moderate to severe obstructive sleep apnea. - The 15-week trial enrolled 298 patients across 28 European sites and demonstrated significant dose-dependent reductions in breathing disturbances and improved nocturnal oxygenation. - Sulthiame was generally well-tolerated with a favorable safety profile, offering a distinct mechanism of action from other investigational OSA treatments. - The positive results were published in The Lancet, marking a potential breakthrough for the estimated 80 million Americans and nearly one billion people worldwide suffering from OSA.